Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | FRG8701 is a new Histamine H2-receptor antagonist with an IC50 of ranging from 0.25 to 0.43 μM. |
Targets&IC50 | H2 receptor:0.25 to 0.43 μM |
In vitro | The inhibitory potency of FRG8701 is almost the same as that of famotidine and approximately 33 times greater than that of cimetidine.Positive chronotropic response to histamine at 10-5 M is dose dependently inhibited by FRG8701 (FRG-8701) famotidine or cimetidine;?and the IC50 values of FRG8701, famotidine and cimetidine are 3.3, 3.0 and 108.6 (×10-7M), respectively. |
In vivo | FRG8701 effectively inhibits the formation of gastric lesions induced by various necrotizing agents, demonstrating its protective effects on the gastrointestinal tract. Oral administration of FRG8701 produces a dose-dependent reduction in the development of gastric lesions caused by stress, indomethacin, and the formation of duodenal ulcers due to mepirizole, with ED50 values ranging from 1.1 to 9.4 mg/kg for gastric lesions and 1.7 to 6.9 mg/kg for each ulcer model. Additionally, in pylorus-ligated rats, intraduodenal delivery of FRG8701 dose-dependently decreases total acid output. Furthermore, FRG8701, whether administered orally or intraperitoneally at doses of 10 or 30 mg/kg, significantly prevents gastric mucosal lesions induced by 0.4 N HCl+50% ethanol, underscoring its potential as a protective agent against gastrointestinal damage. |
Molecular Weight | 418.55 |
Formula | C22H30N2O4S |
Cas No. | 108498-50-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.